Result card

  • SAF5: Does the safety profile of IVIG vary according to mode of production or between different IVIG approved versions or products when used in patients with Mild Cognitive Impairment and Alzheimer’s disease?
English

Does the safety profile of IVIG vary according to mode of production or between different IVIG approved versions or products when used in patients with Mild Cognitive Impairment and Alzheimer’s disease?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund

Internal reviewers: Gerardo Atienza, Lavinia Panait

see TECH domain

Optional
Not
Vignatelli L et al. Result Card SAF5 In: Vignatelli L et al. Safety In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References